• Sonuç bulunamadı

Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

N/A
N/A
Protected

Academic year: 2021

Share "Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN"

Copied!
2
0
0

Yükleniyor.... (view fulltext now)

Tam metin

Referanslar

Benzer Belgeler

[r]

6 Mayıs 1994 Cuma Saat: 10.00 Haftanın Açılışı-Seminer ve Panel M.S.Ü. Sergisi Açılışı ve Kokteyl

Senfoni’sinde, dinleyiciye yansıyan dış kabuğun içinde yaşanan ince, usta işi oymacılık sanatı saklanıyor.. Kimi durumlarda kanın hemen kaynayıvermesi

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No

A regression control chart for autocorrelated processes 241 (Shewhart chart for regression residuals) with estimated parameters of regression equation, and used these charts

SS± 6|QPH] ù $\DVXQ 6 DQG 1ZDQNSD & 2 ³$Q H[DFW PHWKRG IRU FRPSXWLQJ GHOD\ PDUJLQ IRU VWDELOLW\ RI ORDG IUHTXHQF\ FRQWURO V\VWHPV ZLWK FRQVWDQW FRPPXQLFDWLRQ GHOD\V´IEEE

For lift coefficients the literature suggested that asymmetric airfoil NACA 4412 will produce more lift force compared to NACA 0015 in angles of attack from 0 degrees to

Alva: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Research grant/